top of page
Abstract Black Wave
Our Science
Kaerus is developing targeted therapeutics that address an underlying ion channel dysfunction in Fragile X syndrome that contributes to hyper-excitability of the central nervous system in these patients. Our unique mechanistic approach to targeting BK channels has enabled Kaerus to expand focus on other rare genetic syndromes linked to the KCNMA1 gene. You can learn more about Fragile X and these related syndromes below.
1884612574 (Lab Scene 2 scientists by microscope)_edited.jpg
Reach out to learn more
Connect with Kaerus to learn more about our company’s targeted therapeutics programs for Fragile X Syndrome and other rare neurodevelopmental disorders. 
bottom of page